Changes in the composition of the gut microbiota and content of microbial-derived uremic toxins in patients undergoing hemodialysis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Recent data highlight a significant role of the gut microbiota in the pathogenesis of chronic kidney disease, particularly in its terminal stage. However, little is known about the features of intestinal dysbiosis in people undergoing programed hemodialysis. Changes in the intestinal microbiota and blood levels of uremic toxins of microbial origin in patients with terminal renal insufficiency receiving hemodialysis were analyzed. This cross-sectional study included 80 patients receiving hemodialysis and 20 individuals with normal kidney function. The state of the microbiocenosis of the colon was studied using a polymerase chain reaction with a commercial set Colonoflor 16 (premium) manufactured by Alfalab (Russia). Serum levels of trimethylamine and its metabolite trimethylamine-N-oxide were determined by liquid chromatography/mass spectrometry. The concentrations of indoxyl sulfate and p-cresyl sulfate were evaluated by enzyme immunoassay according to the instructions of a commercial kit. In patients undergoing programed hemodialysis, increased colonization of enterococci was combined with the reduction of lacto and bifidophlora, E. coli, ruminococci, bacteria producing short-chain fatty acids (Faecalibacterium prausnitzii, Eubacterium rectale, Roseburia inulinivorans, and Blautia spp.) and microorganisms involved in maintaining the integrity of the intestinal barrier (Bacteroides thetaomicron and Akkermansia muciniphila). In addition, high titer levels of representatives of opportunistic and even pathogenic flora were often found in this group. Intestinal dysbiosis in patients undergoing programed hemodialysis was accompanied by a significant increase in the concentration of uremic toxins in the blood. Compared with individuals with normal renal function, the trimethylamine level in patients undergoing programed hemodialysis was increased 22 times; trimethylamine-N-oxide, 23 times; indoxyl sulfate, 21 times; and p-cresyl sulfate, 5 times. Thus, patients receiving hemodialysis exhibited pronounced pathological changes in intestinal microbiocenosis, accompanied by a significant increase in serum levels of uremic toxins of microbial origin.

About the authors

Mikhail O. Pyatchenkov

Kirov Military Medical Academy

Author for correspondence.
Email: pyatchenkovMD@yandex.ru
ORCID iD: 0000-0002-5893-3191
SPIN-code: 5572-8891

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Evgeniy V. Sherbakov

Kirov Military Medical Academy

Email: evgenvmeda@mail.ru
ORCID iD: 0000-0002-3045-1721
SPIN-code: 6337-6039
Russian Federation, Saint Petersburg

Alexandra E. Trandina

Kirov Military Medical Academy

Email: sasha-trandina@rambler.ru
ORCID iD: 0000-0003-1875-1059
SPIN-code: 6089-3495
Russian Federation, Saint Petersburg

Ruslan I. Glushakov

Kirov Military Medical Academy

Email: glushakoffruslan@yandex.ru
ORCID iD: 0000-0002-0161-5977
SPIN-code: 6860-8990

MD, Dr. Sci. (Med.)

Russian Federation, Saint Petersburg

Klim A. Leonov

Exacte Labs

Email: pyatchenkovMD@yandex.ru
ORCID iD: 0000-0003-4268-1724

MD, Cand. Sci. (Chem.)

Russian Federation, Moscow

Vasily I. Kazey

Exacte Labs

Email: pyatchenkovMD@yandex.ru
ORCID iD: 0000-0003-2032-6289
SPIN-code: 6253-0211

MD, Cand. Sci. (Biol.)

Russian Federation, Moscow

References

  1. Mishima E, Abe T. Gut microbiota dynamics and uremic toxins. Toxins (Basel). 2022;14(2):146. doi: 10.3390/toxins14020146
  2. Tkachenko EI, Grinevich VB, Gubonina IV, et al. Disease as a result of violations of the symbiotic relationship between the host and the microbiota with pathogens. Bulletin of the Russian Military Medical Academy. 2021;23(2):243–252. EDN: OIYFED doi: 10.17816/brmma58117
  3. Pyatchenkov MO, Vlasov AA, Sherbakov EV, et al. Features of assessing the intestinal barrier permeability in chronic kidney disease. Experimental and clinical gastroenterology journal. 2022;(11):46–59. EDN: BLYDXK doi: 10.31146/1682-8658-ecg-207-11-46-59
  4. Pyatchenkov MO, Salikova SP, Sherbakov EV, Vlasov AA. The state of the intestinal microbial-tissue complex in patients with chronic kidney disease. Bulletin of the Russian Military Medical Academy. 2023;25(1):155–164. EDN: RBHWNK doi: 10.17816/brmma124822
  5. Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237. doi: 10.1159/000360010
  6. Voroneanu L, Burlacu A, Brinza C, et al. Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes-A systematic review. J Clin Med. 2023;12(5):1948. doi: 10.3390/jcm12051948
  7. Vaziri ND, Zhao Y-Y, Pahl M. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016;31(5):737–746. doi: 10.1093/ndt/gfv095
  8. Sturov NV, Popov SV, Belikov II. Gut microbiota and the ways to correct it in chronic kidney disease. Indian J Nephrol. 2023;33(3): 162–169. doi: 10.4103/ijn.ijn_469_21
  9. Kornoukhova LA, Emanuel VL, Denisov NL. Routine methods of laboratory studies of intestinal microbiota: role and place in clinical practice. Russian journal of evidence-based gastroenterology. 2021;10(4):5–11. EDN: YKMKPG doi: 10.17116/dokgastro2021100415
  10. Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–315. doi: 10.1038/ki.2012.345
  11. Wehedy E, Shatat IF, Al Khodor S. The human microbiome in chronic kidney disease: a double-edged sword. Front Med (Lausanne). 2022;8:790783. doi: 10.3389/fmed.2021.790783
  12. Zhao J, Ning X, Liu B, et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi: 10.1080/0886022X.2020.1864404
  13. Bhargava S, Merckelbach E, Noels H, et al. Homeostasis in the gut microbiota in chronic kidney disease. Toxins (Basel). 2022;14(10):648. doi: 10.3390/toxins14100648
  14. Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018;67(8):1445–1453. doi: 10.1136/gutjnl-2017-314508
  15. Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017;12:157–170. doi: 10.2217/fmb-2016-0130
  16. Hu Q, Wu K, Pan W, et al. Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China. J Int Med Res. 2020;48(6): 1–12. doi: 10.1177/0300060520926033
  17. Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. PNAS USA. 2019;116(26):12672–12677. doi: 10.1073/pnas.1904099116
  18. Belova IV, Khrulev AE, Tochilina AG, et al. Colon microbiocenosis and its correction in patients receiving programmed hemodialysis. Modern technologies in medicine. 2020;12(5):62–70. EDN: ZPWVRM doi: 10.17691/stm2020.12.5.07
  19. Noce A, Marchetti M, Marrone G, et al. Link between gut microbiota dysbiosis and chronic kidney disease. Eur Rev Med Pharmacol Sci. 2022;26(6):2057–2074. doi: 10.26355/eurrev_202203_28354
  20. Pyatchenkov MO, Vlasov AA, Sherbakov EV, Salikova SP. Microbial-derived uremic toxins: role in the pathogenesis of comorbidities in patients with chronic kidney disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(3):7–15. EDN: DZGPXN doi: 10.22416/1382-4376-2023-33-3-7-15
  21. Kryukov EV, Potekhin NP, Chaplyuk AL, et al. Expert approaches to chronic kidney disease. Military medical journal. 2016;337(10): 13–18. EDN: XBTEMF doi: 10.17816/RMMJ73839

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies